retatrutide clinical benefits Today, we shared new data from two Phase 3 trials of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v Retatrutide in Singapore: A Comprehensive

Pharmacology and clinical development of GIP/GLP-1/glucagon triple agonists

weight loss was still continuing 100% of participants on 8mg or 12mg achieved at least 5% weight loss (the threshold for health benefits) 83% on 12mg achieved 15% weight loss, which is considered exceptional How Retatrutide Compares to Other GLP-1 Medications Each additional receptor target correlates with greater weight loss

van Galen et al., 2023

Dont ignore persistent symptoms If fatigue is getting worse or making it hard to function, speak to your pharmacist or GP

Early regrowth may become visible as short, fine hairs appearing along the hairline and part line

Research from ACR Convergence 2025 highlighted GLP-1 receptor agonists as showing particular promise in psoriatic arthritis management, where the dual burden of skin and joint disease creates challenges for conventional therapies